Table 1 Demographic data of the included posts and N, N-DMT experiences.

From: Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience

Variables

N (%) or median (IQR)

Posts, n (%)

3305 (100.0)

Authors, n (%)

2277 (68.9)

Deleted author, n (%)

351 (10.6)

Experiences, n (%)

3778 (100.0)

Word count, median (IQR)

311.0 (160.0, 568.0)

Age (years), median (IQR)a

23.0 (20.0, 29.8)

Gender

Male

189 (5.0)

Female

48 (1.3)

Setting, n (%)

Inside (including inside NOS)

969 (25.6)

 Bedroom or living room

492 (13.0)

 Vehicle

23 (0.6)

 Bathroom, shower, or bath

10 (0.3)

Outside (including outside NOS)

169 (4.5)

 Forest, jungle, beach, or tent

39 (1.0)

 Backyard, garden, park, or cemetery

22 (0.6)

Music

408 (10.8)

Sitters

 Alone

157 (4.2)

 Not alone or sitter present

791 (20.9)

Dose (mg), median (IQR)b

40.0 (27.5, 50.0)

Dose (number of inhalations), median (IQR)c

3.0 (2.0, 3.0)

Extraction source

Mimosa hostilis root bark

95 (2.5)

Acacia confusa root bark

34 (0.9)

Device, n (%)

Pipe or glass pipe NOS

598 (15.8)

Vaporizer NOS

253 (6.7)

Bong

185 (4.9)

Dab rig

155 (4.1)

Home-made device ("machine" or bottle-pipe)

138 (3.6)

Plant-based accompaniments, n (%)

Sandwich method

259 (6.8)

Changa

165 (4.4)

Enhanced leaf, joint, or blunt

21 (0.6)

Trip duration (min), median (IQR)d

10.0 (5.0, 15.0)

Previous inhaled DMT use, n (%)

0

1008 (26.6)

1

324 (8.6)

Multiplef

620 (16.4)

Yes NOS

631 (16.7)

Previous non-inhaled-DMT psychedelic use, n (%)g

No previous psychedelic use

76 (2.0)

LSD

550 (14.6)

Psilocybin

383 (10.1)

MDMA

80 (2.1)

Otherh

150 (4.0)

Yes NOS

66 (1.7)

Concomitant psychoactive substance use, n (%)g

536 (14.2)

Cannabis

243 (6.4)

LSD

129 (3.4)

Alcohol or benzodiazepines

101 (2.7)

MDMA

40 (1.1)

Psilocybin

30 (0.8)

Otheri

33 (0.9)

  1. Reported in a118 experiences (3.1%), b1347 experiences (35.7%), c1087 experiences (28.8%), and d538 experiences (14.2%).
  2. fGreater than one previous inhaled DMT experiences or multiple previous experiences NOS.
  3. gDoes not summate to 100% due to multiple identified within an index experience.
  4. hIncluding Salvia, 2C Class, Ayahuasca, 25B-NBOMe, ketamine, mescaline (or peyote), alpha-methyltryptamine, and ibogaine.
  5. iIncluding ketamine, stimulants, cocaine, opioid, or mescaline.
  6. 4-AcO-DMT 4-Acetoxy-N,N-dimethyltryptamine, 5-MeO-DMT 5-methoxy-N,N-dimethyltryptamine, DMT dimethyltryptamine, IQR inter-quartile range, LSD lysergic acid diethylamide, MDMA 3,4-methyl enedioxy methamphetamine, mg milligrams, min minutes, NOS not otherwise specified.